NCT04235998

Brief Summary

The value of lung ultrasound in the work up of pleural effusion (fluid in between the thin doublet layered film surrounding the lungs) is unknown. The researchers will perform a systematic lung ultrasound scan including a scan for extra thoracic metastasis (spread of cancer to other organs) in the lymphnodes of the neck and metastasis lever in 56 patients one-sided pleural effusion. The researchers will measure if the interventions change the diagnostic plan for the patient and leads to faster diagnostics of the underlying course.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
57

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 19, 2019

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 22, 2020

Completed
26 days until next milestone

Study Start

First participant enrolled

February 17, 2020

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 20, 2020

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 6, 2021

Completed
Last Updated

May 11, 2022

Status Verified

May 1, 2022

Enrollment Period

9 months

First QC Date

December 19, 2019

Last Update Submit

May 10, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Proportion of cases where systematic lung ultrasound (LUS) change the planned diagnostic process for patients with unilateral pleural effusion.

    Information found in electronic patient files. Comparison of diagnostics planned before systematic ultrasound and diagnostics planned after systematic ultrasound. Measured in proportion of included patients

    26 weeks post procedure

Secondary Outcomes (7)

  • Characteristics of ultrasonic findings with additional systematic LUS.

    Day 1, within 30 minutes after the end of procedure

  • Proportion of cases where findings of clinical importance on systematic LUS were not identified at the initial contrast-enhanced CT thorax or PET-CT

    Day 1 within 30 minutes after the end of procedure

  • Proportion of cases where the change in the diagnostic process after LUS provide a diagnose

    26 weeks post procedure

  • The patient experienced pain during procedure score

    Day 1 within 30 minutes after the end of procedure

  • Patient experienced time consumption

    Day 1 within 30 minutes after the end of procedure

  • +2 more secondary outcomes

Study Arms (1)

Systematic lung ultrasound

Patients with unilateral pleural effusion of unknown course

Diagnostic Test: Systematic lung ultrasound

Interventions

Patients will undergo a systematic lung ultrasound including review of: * Sonographic characteristic of effusion * Parietal, diaphragmatic and visceral pleura * Pleural nodules * Lung parenchyma * Extra pulmonary findings: Hepatic pathology, enlarged lymph nodes of the neck and a cardiac assessment.

Systematic lung ultrasound

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients referred to the Pleura Clinic (an outpatient clinic in the Department of Pulmonary Disease, Næstved Sygehus, on of two regional centers for work up of pulmonary malignancy ) from the general practitioner or from other hospital departments both Næstved Sygehus and other hospitals.

You may qualify if:

  • Age ≥ 18 years.
  • Unilateral pleural effusion of unknown course.
  • Patients must be able to give informed consent.

You may not qualify if:

  • Bilateral pleural effusions.
  • Known cause of pleural effusions.
  • Life expectancy \<3 months.
  • Inability to understand written or spoken Danish.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Næstved Sygehus, department of pulmonary medicine

Næstved, Region Sjælland, 4700, Denmark

Location

MeSH Terms

Conditions

Pleural EffusionPleural Effusion, Malignant

Condition Hierarchy (Ancestors)

Pleural DiseasesRespiratory Tract DiseasesPleural NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasms

Study Officials

  • Uffe Bødtger, MD, PhD

    Department of Pulmonary Medicin, Næstved Sygehus

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 19, 2019

First Posted

January 22, 2020

Study Start

February 17, 2020

Primary Completion

November 20, 2020

Study Completion

May 6, 2021

Last Updated

May 11, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will not share

Locations